Health Dictionary Find a Doctor

Herpes simplex direct detection of genital lesions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lakshmi Gopalakrishnan, M.B.B.S.

Overview

The confirmation and characterization of the infection and its type by direct detection of herpes simplex virus in genital lesions is essential for diagnosis, prognosis, counseling, and management. Cell culture and PCR are the preferred HSV tests for people seeking medical treatment for genital ulcers or other mucocutaneous lesions. The sensitivity of viral culture is low, especially for recurrent lesions, and declines rapidly as lesions begin to heal. PCR assays for HSV DNA are more sensitive and are increasingly used in many settings.[1][2] PCR is the test of choice for detecting HSV in spinal fluid for diagnosis of HSV infection of the central nervous system. Viral culture isolates should be typed to determine which type of HSV is causing the infection. Failure to detect HSV by culture or PCR does not indicate an absence of HSV infection, because viral shedding is intermittent. The use of cytologic detection of cellular changes of HSV infection is an insensitive and nonspecific method of diagnosis, both for genital lesions (i.e., Tzanck preparation) and for cervical Pap smears and therefore should not be relied upon.

British Association for Sexual Health and HIV (BASHH) Recommendations[3]

  • Methods should be used that directly demonstrate HSV in swabs or scrapings from a lesion.
  • Cytological examination (Tzanck and Papanicolaou smears) has modest diagnostic specificity and sensitivity and should not be relied upon for diagnosis.
  • HSV isolation in cell culture is the diagnostic gold standard and the current routine diagnostic method.
  • Isolates can be typed and tested for antiviral susceptibility.
  • Virus culture is slow, labor-intensive and expensive.
  • Specificity is virtually 100%, but levels of virus shedding, quality of specimens, and transport conditions influence sensitivity. First-episode ulcers more often yield the virus than recurrent lesions (82% versus 43%). Average sensitivity is 52% to 93% for vesicles, 41% to 72% for ulcers and 19% to 27% for crusted lesions. Delayed sample processing and lack of specimen refrigeration after collection and during transport significantly reduce the yield of virus culture.
  • HSV DNA detection by polymerase chain reaction (PCR) increases HSV detection rates by 11 to 71% compared with virus culture. HSV PCR is widely available for testing of cerebrospinal fluid in patients with neurological disease. There have been at least 14 large studies comparing virus culture with PCR for the detection of HSV in muco-cutaneous swabs, together comprising data from over 3,500 patients. These studies demonstrated that the relative sensitivity of virus culture averaged 70% and ranged between 25% and 89%. PCR should be implemented, after local validation, as the preferred diagnostic method for genital herpes.
  • Unlike virus culture, PCR-based methods do not rely on virus growth and may allow less stringent conditions for sample storage and transport.
  • Real-time PCR assays allow detection and typing of HSV in a single reaction tube, with faster turn-around-times (potentially 2 hours) and lower risk of contamination than traditional PCR assays.
  • Viral antigen can be detected by direct immunofluorescence assay (IFA) using fluorescein-labelled monoclonal antibodies on smears, or by enzyme immunoassay (EIA) on swabs.
  • IFA shows lower sensitivity (74%) and specificity (85%) than virus culture and cannot be recommended.
  • Commercially available EIAs (e.g., HerpChek, PerkinElmer, Belgium) show ≥ 95% specificity and 62% to 100% sensitivity relative to virus culture. Sensitivity may be higher than virus culture for typical presentations and late specimens, but lower for cervical or urethral swabs and recurrent episodes. HerpChek does not differentiate between HSV types.

BASHH guidelines mentioned in National Guideline Clearinghouse

References

Template:WH Template:WS

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH